Marina Garassino, MD, University of Chicago, Chicago, IL, discusses the treatment of advanced non-small cell lung cancer (NSCLC) in 2021, highlighting regimens which combine chemotherapy and immunotherapy. Dr Garassino outlines key trials including the Phase III KEYNOTE-189 trial (NCT02578680) and the Phase III KEYNOTE-407 trial (NCT02775435) of chemotherapy with or without pembrolizumab in first-line metastatic non-squamous NSCLC, and the IMpower150 trial (NCT02366143) of atezolizumab plus carboplatin and paclitaxel with or without bevacizumab compared to carboplatin-paclitaxel-bevacizumab in stage IV non-squamous NSCLC. Finally, Dr Garassino gives an overview of the Phase III CheckMate 9LA trial (NCT03215706) investigating nivolumab plus ipilimumab with chemotherapy compared to chemotherapy alone in first-line treatment of NSCLC. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.
Marina Garassino has received personal fees or grants from AstraZeneca, MSD, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Inivata, Novartis, Pfizer, Roche, Takeda, Seattle Genetics, Mirati Therapeutics, Daiichi Sankyo, Bayer, GlaxoSmithKline S.p.A, Sanofi-Aventis,, Blueprint Medicine, Janssen and Regeneron Pharmaceuticals; and has received institutional fees or grants from Eli Lilly, Pfizer, AstraZeneca, MSD, BMS, Celgene, Incyte, MedImmune, Novartis, Pfizer, Roche, Tiziana Sciences, GlaxoSmithKline S.p.A, Spectrum Pharmaceuticals, Clovis, Merck Serono, Bayer, Sanofi-Aventis, Blueprint Medicine, Merck KGaA, Ipsen, Exelisis, Otsuka Pharma, Janssen and Spectrum Pharmaceuticals.